New clinical trial: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease

[Farooqji]

clinicaltrials.gov/ct2/show...

Contacts

Contact: Johannes Levin, MD+49-6734-9622 ext [e-mail]

Contact: Armin Giese, MD+49-6734-9622 ext [e-mail]

Locations

United Kingdom

Quotient Sciences

Nottingham, United Kingdom, NG11 6JS

Sponsors and Collaborators

MODAG GmbH

Aptuit (Verona) Srl, an Evotec Company

Quotient Sciences

Nottingham University Hospitals NHS Trust

Investigators

Principal Investigator:Nand Singh, BSc, MD, DPM, MFPMQuotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK

Principal Investigator:Jonathan Evans, MD

[Bolt_Upright]

This looks promising. They are recruiting now.

parkinsonsnewstoday.com/202...

A Phase 1 clinical trial in the U.K. is recruiting patients with mild to moderate Parkinson’s to assess MODAG Neuroscience Solutions‘ investigational oral therapy anle138b, which seeks to slow or halt disease progression.

The trial (NCT04685265) will be conducted at a single site at Nottingham University Hospital, in central England, according to a press release from Cure Parkinson’s. Researchers are looking to enroll 24 adults, ages 50 to 80, who are able to walk unaided.

More information on enrollment is available here, as well as by email. Patients in the U.K. may get additional information via telephone, by calling 03303 031 000.

“Anle138b is taken by mouth, easily enters the brain, and preclinical research indicates that it is very good at reducing levels of aggregated [clumped] alpha synuclein [protein] inside cells. The reduction of alpha-synuclein in the brain has been reported to reverse Parkinson’s-like motor symptoms in animal models,” Cure Parkinson’s says on its website.

[Hidden]

scienceofparkinsons.com/202...